Pomerantz Law Firm Issues Investor Alert Regarding Capricor Therapeutics Class Action Lawsuit Deadlines

Investor Alert: Class Action Lawsuit Against Capricor Therapeutics, Inc.

Pomerantz LLP has announced a significant class action lawsuit targeting Capricor Therapeutics, Inc. (NASDAQ: CAPR), focusing on allegations that the company and its executives may have engaged in securities fraud and other unlawful activities. Investors who faced losses due to investments in Capricor are encouraged to take action before the upcoming legal deadlines.

Background of the Case

The lawsuit stems from Capricor's Biologics License Application (BLA) for Deramiocel, a therapy aimed at addressing Duchenne muscular dystrophy, which was filed with the FDA in late 2024. Unfortunately, this application was met with a Complete Response Letter (CRL) from the FDA in July 2025, indicating that the submission lacked substantial evidence of effectiveness and required further clinical data. Capricor claims they have since addressed these issues prior to the critical advisory committee meeting held on July 29, 2026.

In the lead-up to this meeting, the FDA released briefing documents that raised significant concerns regarding Capricor's revision of its statistical analysis plan (SAP). Notably, the document criticized the alteration made to the SAP, which was submitted just a day before the data was unblinded. This prompted the FDA to describe Capricor's analyses as exploratory rather than definitive, which negatively impacted the perception of Deramiocel's benefit-risk profile.

As a direct consequence of these developments, Capricor's stock price saw a dramatic decrease, plummeting by 64% to $7.00 per share on July 27, 2026. The downward trend continued after the advisory panel's non-binding vote indicated that the evidence available did not support Deramiocel’s efficacy, ultimately causing the stock to drop to $4.19 per share.

Legal Implications and Class Action Details

Investors who had purchased or acquired Capricor's securities during the designated Class Period may be eligible to join the class action. The deadline to seek appointment as the Lead Plaintiff is set for September 28, 2026. Interested individuals are instructed to reach out to Pomerantz's Danielle Peyton for further guidance, ensuring to provide essential contact details and purchase information.

About Pomerantz LLP

Founded by the late Abraham L. Pomerantz, a pioneer in the field of securities class action law, Pomerantz LLP has established itself as a respected firm known for advocating victims of securities fraud. With more than 85 years of experience, the firm continues to pursue justice for its clients and has secured substantial damages for class members in numerous high-profile cases. Their expertise is widely acknowledged across locations including New York, Chicago, Los Angeles, London, and beyond.

Conclusion

The unfolding situation surrounding Capricor Therapeutics serves as a crucial reminder for investors to stay informed and proactive regarding their legal rights. The upcoming deadlines for the class action lawsuit mark a pivotal moment for affected individuals. Those who believe they have been wronged are encouraged to take action swiftly to seek justice and accountability in the capital markets.

For more information about the lawsuit, investors can visit Pomerantz Law Firm's website for updates and resources.

Disclaimer: The information provided here is intended for educational purposes only and should not be construed as legal advice. Investors should consult with a qualified attorney regarding their specific circumstances.